The CROWN Study: Design, Context, and the Clinical Significance of 7-Year Follow-Up Data

This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC. Dr. Lovly sets the stage by contextualizing the study's scope: 296 treatment-naive patients randomized 1:1 to receive either lorlatinib — a third-generation ALK tyrosine kinase inhibitor dosed at 100 mg once daily — or crizotinib at 250 mg twice daily, with a primary endpoint of progression-free survival and secondary endpoints including overall survival, intracranial progression, and safety.

The discussion then turns to a question that anchors the entire program: why does a 7-year follow-up period matter so profoundly? Drs. Lovly and Shaw reflect on how far the field has come, recalling that prior to the era of targeted therapies, median survival for patients with advanced NSCLC was less than 12 months. Against that backdrop, the fact that 44% of patients on lorlatinib were still on therapy at the time of the data cutoff — compared to just 3% on crizotinib — speaks to a level of treatment durability that is genuinely unprecedented in solid tumor oncology. As Dr. Shaw notes, 7-year follow-up data of this kind has simply never been seen before in this disease.

The segment also explores which clinical endpoints matter most to patients and providers alike. Dr. Shaw identifies progression-free survival as arguably the most meaningful metric — representing real time that patients live without cancer worsening — while also underscoring the importance of response rate, intracranial disease control (particularly given that up to 30% of ALK-positive patients present with brain metastases), and long-term safety, all of which are critical considerations when a patient may remain on therapy for many years.